IPSS | Mean (SD) (Standard deviation) | Distribution | Source |
---|---|---|---|
Initial IPSS | 23.5 (4.96) | Normal | [5] |
IPSS progression per 3-month cycle | |||
FT | − 3.00 (3.32) | Normal | [5] |
Combination therapy, 1st cycle | − 4.80 (0) | - | [6] |
Combination therapy | − 0.20 (0.21) | Normal | [6] |
5-ARI, 1st cycle | − 2.80 (0) | - | [6] |
5-ARI | − 0.31 (0.28) | Normal | [6] |
α-blockers, 1st cycle | − 4.50 (0) | - | [6] |
α-blockers | 0.05 (0.19) | Normal | [6] |
Natural, off treatment | 0.045 (0.305) | Normal | [11] |
Surgery effect on IPSS | |||
TURP, percent change in IPSS | 0.27 (0.22) | Beta | [12] |
PVP, IPSS value different from TURP | 0.46 (2) | Normal | [12] |
UroLift, percent change in IPSS | 0.50 (0.34) | Beta | [13] |
HoLEP, IPSS value different from TURP | − 0.78 (0.31) | Normal | [14] |
No. of cycles | Lower/upper bound | Distribution | Source |
No. of cycles to reach maximum effect | |||
FT | 2/3 | Uniform | [5] |
Combination therapy | 6/10 | Uniform | [6] |
5-ARI | 6/10 | Uniform | [6] |
α-blockers | 15/17 | Uniform | [6] |
No. of cycles effect lasts | |||
FT | 16/31 | Triangle | [5] and clinical expert opinion |
TURP | 16/31 | Triangle | |
PVP | 16/31 | Triangle | |
UroLift | 16/31 | Triangle | [13] |
HoLEP | 16/31 | Triangle | [14] |